UK Pompe Disease Pricing Strategy Model

Alglucosidase alfa (Lumizyme/Myozyme) has been commissioned by NHS England as a highly specialised service since 2014 under a clinical commissioning policy rather than a formal NICE technology appraisal. A confidential Patient Access Scheme brings net cost to an estimated £200,000 to £350,000 per patient per year for the roughly 180 UK patients currently on ERT. Avalglucosidase alfa (Nexviazyme) has since cleared NICE under TA821, with its own confidential commercial arrangement, carrying an estimated 20 to 30 percent WAC premium over alglucosidase. The defined switch-eligible population, the roughly 45 to 50 patients showing FVC decline despite alglucosidase, keeps the incremental NHS budget impact to a manageable £2 to 4 million a year; broader first-line uptake would be a materially larger budget event.

The harder number sits behind the TA821 recommendation, not in front of it: the pre-PAS cost-effectiveness case for avalglucosidase's incremental FVC and 6MWT improvement over alglucosidase runs an estimated £1 to 4 million per QALY, a genuinely difficult ICER profile that only cleared NICE's HST threshold after deep confidential discounting. A stronger case exists in the ventilator-avoidance argument: each year of mechanical-ventilation dependency avoided carries an estimated 0.36 QALY gain, a materially larger utility case than incremental walk-distance improvement alone. Any new entrant's pricing strategy should build around that ventilator-avoidance value rather than compete on the same incremental-FVC comparator that required avalglucosidase's heavy PAS discount to clear.

Every AXLRx pricing model is built from primary NHS and NICE sources, not secondary summaries. Findings are independently verified before inclusion.

Pompe UK pricing sources: NHS England Pompe commissioning policy documentation (2014), NICE technology appraisal TA821 (avalglucosidase alfa, final guidance), the COMET trial evidence base, and UK Pompe Consortium outcomes registry 2023.